Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
vitiligo
Biotech
Incyte’s vitiligo bet scores ph. 3 wins but can’t shake off Rinvoq
Incyte’s povorcitinib has scored a pair of phase 3 wins for a skin condition, although analysts noted the prospect didn’t quite live up to Rinvoq.
James Waldron
Apr 28, 2026 9:52am
Teva lines up $500M in Royalty Pharma funding for vitiligo drug
Jan 12, 2026 7:10am
Incyte scraps BET inhibitor and anti-CD122 drug
Oct 28, 2025 9:05am
Vyne's BET inhibitor fails phase 2 vitiligo trial, sinking stock
Jul 30, 2025 9:35am
Sugar from soil bacteria restores pigment in mice with vitiligo
Jan 31, 2025 1:32pm
'Expect us to act' on M&A, AbbVie CEO says
Feb 9, 2023 2:29pm
